small molecule

SOHONOS

PALOVAROTENE

Loss of exclusivityJune 2037latest FDA-listed patent expiry

CompanyIPSEN BIOPHARMACEUTICALS INC

Drug detail

Brand name	SOHONOS
Active ingredient	PALOVAROTENE
Strength	5MG
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	August 2023
Marketing status	RX

Listed patents

Patent	Expires	Type
11622959	June 2037	use U-3676
10864194	June 2037	use U-3676
12458626	June 2037	use U-3676
12138245	June 2037	use U-4031
12201614	June 2037	use U-4031
12023312	August 2031	use U-3966
10292954	August 2031	use U-3676
9789074	August 2031	use U-3676
9314439	August 2031	use U-3676

Regulatory exclusivity

Code	Expires
ODE-439	August 2030
NCE	August 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from IPSEN BIOPHARMACEUTICALS INC